Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

Colorful awareness ribbons representing multiple cancer types on pink background

New drug quadruples three-year survival rates for mesothelioma in international trial

By / / Good News For Humankind

Mesothelioma survival rates have quadrupled over three years thanks to a drug that starves tumors of a key nutrient, marking the first successful new treatment combination for the disease in 20 years. The international ATOMIC-meso trial, led by Queen Mary University of London and published in JAMA Oncology, found that patients receiving pegargiminase alongside standard chemotherapy were significantly more likely to be alive three years later. The drug works by depleting arginine in the bloodstream, cutting off a nutrient that mesothelioma cells cannot produce themselves. For a cancer caused by asbestos exposure that has historically offered patients months rather than years, this breakthrough represents a genuine turning point.

Assortment of pills, for article on AI antidepressant prediction

Novel AI model rapidly determines if an antidepressant will work

By / / Good News For Humankind

Antidepressant treatment has long meant weeks of waiting, side effects, and uncertainty — and for around 60% of people with depression, the first medication simply doesn’t work. Dutch researchers developed an AI model that predicts within one week whether sertraline will help a patient by reading brain blood flow patterns and early symptom changes, potentially allowing clinicians to pivot sooner for those unlikely to respond. The model is limited to sertraline and requires further validation before clinical use — but it points toward a future where prescribing depression treatment looks less like guesswork and more like precision medicine.

Depiction of nerve cells, for article on non-opioid compound

Researchers discover an effective non-opioid treatment for nerve pain

By / / Good News For Humankind

Nerve pain affects an estimated one in ten adults in the U.S., and for many, nothing currently available offers real relief. A new compound called FEM-1689 reduced pain hypersensitivity in mice with diabetic and chemotherapy-induced neuropathy, working through a receptor entirely separate from opioid pathways and sidestepping addiction risk. The same cellular effect was observed in human neurons in the lab. All results remain pre-clinical, and many promising compounds fail before reaching patients. But the mechanistic clarity here puts a genuinely safer treatment for one of medicine’s most stubborn problems on much firmer ground.

Empty office desk and chairs, for article on four-day workweek trial

Germany launches large four-day workweek trial

By / / Good News For Humankind

Four-day workweek research is gaining serious momentum, and Germany’s new pilot puts it to the test in one of the world’s most productivity-focused economies. Forty-five companies joined a six-month trial, maintaining full pay while cutting hours by 20% — a genuine business bet, not an academic exercise. Earlier U.K. trials showed promising results, though critics note that only companies already suited to compressed schedules tend to volunteer, limiting how broadly findings apply. Still, each new dataset strengthens the global case that working less might mean working better.

Chromosomes, for article on CRISPR gene therapy hereditary angioedema

Gene therapy hailed as ‘medical magic wand’ for hereditary swelling disorder

By / / Good News For Humankind

CRISPR gene editing has freed ten patients with hereditary angioedema from the sudden, sometimes life-threatening swelling attacks that shaped their daily lives, with several remaining attack-free for 18 months and counting after a single infusion. The therapy works by switching off a gene in liver cells, stopping the painful chain reaction at its source rather than just managing symptoms. One participant who used to have attacks every three weeks has needed no medication since. Doctors are now recruiting for a phase-three trial, building on the same Nobel-winning technology that recently produced an approved cure for sickle cell disease. For a rare condition long defined by unpredictability and fear, it’s a glimpse of what gene editing could mean for millions living with inherited illness worldwide.

Back of a school bus, for article on electric school buses

Miami commits to putting 100 electric school buses on the road

By / / Good News For Humankind

Electric school buses are about to transform the daily commute for Miami-Dade students, with the district rolling out 100 of them thanks to a $19.1 million EPA grant, a Volkswagen award, and the school system’s own early investment. That makes it one of the largest electric school bus fleets in the country. The shift means cleaner air for kids waiting at the curb and quieter rides for the drivers behind the wheel, with no tailpipe emissions along the route. Miami-Dade’s blended funding approach — district dollars, federal support, and a corporate settlement — offers a model other communities can follow as the movement to electrify America’s roughly 480,000 school buses gathers speed.

Person having blood drawn, for article on Alzheimer's blood test

Breakthrough Alzheimer’s blood test could detect disease 15 years before symptoms emerge

By / / Good News For Humankind

A simple Alzheimer’s blood test trialed in Sweden can detect the disease’s biological signs up to 15 years before symptoms appear, matching the accuracy of a spinal tap in a study of 786 people. The test measures p-tau217, a protein that builds up in the blood as Alzheimer’s-related changes unfold in the brain. Researchers suggest it could one day be as routine as a cholesterol check for anyone over 50, replacing painful lumbar punctures and hard-to-access specialist scans. With one in three people born in the U.K. today expected to develop dementia, catching the disease early — while there’s still time to intervene — could transform how the world confronts one of its most feared illnesses.

Close-up of a mosquito perched on a green leaf, relevant to malaria vaccine news

Cameroon launches the world’s first routine malaria vaccine program

By / / Good News For Humankind

Malaria vaccine rollout reached a historic milestone in January 2024 when Cameroon became the first country to administer the RTS,S vaccine, also known as Mosquirix, as part of a routine national immunization program. More than 662,000 doses began reaching children across the country, targeting a disease responsible for 95% of global malaria deaths, most among children under five. The moment caps over 35 years of development and a successful WHO recommendation in 2021. With 19 additional African countries planning to follow, the rollout could eventually protect millions of children each year.

Manhattan skyline, for article on medical debt relief

New York City plans to wipe out $2 billion in medical debt for 500,000 residents

By / / Good News For Humankind

Medical debt relief is coming to New York City in a big way: a new program will wipe out more than $2 billion in unpaid medical bills for as many as 500,000 residents, no application required. The city is spending $18 million over three years and partnering with the nonprofit RIP Medical Debt, which buys debt portfolios for pennies on the dollar and simply cancels them. Eligible families will just receive a letter letting them know their balance is gone. With roughly 100 million Americans carrying some form of health care debt, this kind of municipal action offers a hopeful template — one that treats medical debt not as private misfortune, but as something cities can actually help fix.

Doctor holding vial of HPV vaccine, for article on HPV vaccination

No cervical cancer cases in HPV-vaccinated women in Scotland

By / / Good News For Humankind

Scotland’s HPV vaccine programme has produced a landmark result: zero cervical cancer cases among women who got the full vaccine series at age 12 or 13. Researchers reached that finding by tracking every woman in Scotland eligible for cervical screening since the programme launched in 2008, making it one of the most comprehensive studies of its kind. Pairing early vaccination with routine screening is what’s driving the result, and Public Health Scotland says the combination could turn cervical cancer into a rare disease. For countries where cervical cancer still kills tens of thousands of women each year, especially those without strong screening systems, this is powerful proof that prevention at scale really works.